-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Humanigen, a clinical biopharmaceutical company, announced today that the U.S. Patent and Trademark Office has granted the company a patent for cytokine storms and neurotoxicity in patients treated with the chilayer antigen recipient T (CAR-T) cells using lenzilumab.
patent covers the use of lenzilumab for the prevention or treatment of cytokine release syndrome (CRS) and neurotoxicity in patients treated with CAR-T cells.
Lenzilumab is combined and mesothetic with granulocyte macrophage cluster stimulation factors (GM-CSF), which is considered a key factor in triggering toxic reactions associated with CAR-T cell therapy, such as CRS and neurotoxicity.
Believe that lenzilumab may play an important role in enhancing CAR-T cell therapy, and we are committed to driving the development of lenzilumab to address cytokine storms associated with CAR-T cell therapy and other cytotherapy," said Cameron Durrant, M.D., M.D.
patent emphasizes the pioneering approach to neutrality with GM-CSF with lenzilumab."
。